Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
N

NeoPharm Co Ltd
KOSDAQ:092730

Watchlist Manager
NeoPharm Co Ltd
KOSDAQ:092730
Watchlist
Price: 22 950 KRW -0.86% Market Closed
Market Cap: ₩367.9B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
NeoPharm Co Ltd

Wall Street analysts forecast NeoPharm Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NeoPharm Co Ltd is 30 600 KRW with a low forecast of 30 300 KRW and a high forecast of 31 500 KRW.

Lowest Forecast
Wall Street Target
₩30 300
32% Upside
Average Forecast
Wall Street Target
₩30 600
33% Upside
Highest Forecast
Wall Street Target
₩31 500
37% Upside
Lowest Forecast
Price Target
30 300 KRW
32% Upside
Average Forecast
Price Target
30 600 KRW
33% Upside
Highest Forecast
Price Target
31 500 KRW
37% Upside
NeoPharm Co Ltd Competitors:
Price Targets
NRG
NRJ Group SA
59% Upside
I
INCOAX
InCoax Networks AB
80% Upside
NRG
NRJ Group SA
59% Upside
I
INCOAX
InCoax Networks AB
80% Upside

Revenue
Forecast

16% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
16% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 16%. The projected CAGR for the next 3 years is 17%.

What are analyst estimates?

Gross Profit
Forecast

15% / Year
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
15% / Year
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 24%.

What are analyst estimates?

Operating Income
Forecast

46% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
46% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 46%. The projected CAGR for the next 3 years is 18%.

What are analyst estimates?

Pre-Tax Income
Forecast

39% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
39% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 39%. The projected CAGR for the next 3 years is 25%.

What are analyst estimates?

Net Income
Forecast

34% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
34% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 34%. The projected CAGR for the next 3 years is 15%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is NeoPharm Co Ltd's stock price target?
Price Target
30 600 KRW

According to Wall Street analysts, the average 1-year price target for NeoPharm Co Ltd is 30 600 KRW with a low forecast of 30 300 KRW and a high forecast of 31 500 KRW.

What is the Revenue forecast for NeoPharm Co Ltd?
Projected CAGR
17%

Over the last 13 years, the compound annual growth rate for Revenue has been 16%. The projected CAGR for the next 3 years is 17%.

What is the Gross Profit forecast for NeoPharm Co Ltd?
Projected CAGR
24%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 24%.

What is the Operating Income forecast for NeoPharm Co Ltd?
Projected CAGR
18%

Over the last 13 years, the compound annual growth rate for Operating Income has been 46%. The projected CAGR for the next 3 years is 18%.

What is the Pre-Tax Income forecast for NeoPharm Co Ltd?
Projected CAGR
25%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 39%. The projected CAGR for the next 3 years is 25%.

What is the Net Income forecast for NeoPharm Co Ltd?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Net Income has been 34%. The projected CAGR for the next 3 years is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join 356,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett